In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.
|Journal||Case Reports in Clinical Pathology|
|Publication status||Published - 2014|
- Hepatocellular carcinoma
- Radiation therapy